GLUE
Neutral signalScored 2026-07-29 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Monte Rosa Therapeutics, Inc.
- Nom
- Monte Rosa Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $910.1M
- Employés
- 173
- PDG
- Markus Warmuth
- Site web
- https://www.monterosatx.com
- Marché
- ARVNCCCCNRIX
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 19 500 titres (~451 318,55 $ US)
- Insiders
- Warmuth MarkusManning Anthony M.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$137
Avg sell (VWAP, 90d window) $10.56 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-19 21:57:14
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew | Sell · S | 13 | $10.56 | $137 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-07-29 Drivers: fundamentals. Moteurs : fondamentaux.
GLUE presents a structurally weak fundamental profile: despite adequate near-term liquidity (score: 85), persistent negative operating margins, heavy cash burn from R&D/SG&A, and a poor fundamental trend score (35)…
The first sentence of the analysis written for GLUE on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 6.12 · operating margin -44% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 93.2% | 89.3% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -32.1% | -92.7% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -25.4% | -82.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -43.8% | -107.3% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -32.1% | -92.7% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -31.2% | -96.1% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 6.123 | 2.405 | 5.070 | 10.790 | 20.956 | |
| Quick Ratio | 6.123 | 2.405 | 5.070 | 10.790 | 20.956 | |
| Solvency Ratio | -0.140 | -0.299 | -1.037 | -1.476 | -3.818 | |
| Cash Ratio | 2.023 | 1.429 | 2.749 | 2.148 | 20.800 | |
| Price To Earnings Ratio | -26.576 | -7.082 | -2.148 | -3.309 | -12.843 | |
| Price To Earnings Growth Ratio | 0.668 | 0.113 | -0.150 | -0.074 | -0.137 | |
| Forward Price To Earnings Growth Ratio | 0.668 | 0.113 | -0.150 | -0.074 | -0.137 | |
| Price To Earnings Diluted Ratio | -26.576 | -7.082 | -2.148 | -3.309 | -12.843 | |
| Price To Earnings Diluted Growth Ratio | 0.668 | 0.113 | -0.150 | -0.074 | -0.137 | |
| Price To Book Ratio | 4.410 | 2.301 | 1.620 | 1.324 | 2.734 | |
| Price To Sales Ratio | 8.310 | 6.783 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -37.375 | 13.495 | -4.621 | -3.411 | -13.753 | |
| Price To Operating Cash Flow Ratio | -45.080 | 12.214 | -6.630 | -3.887 | -16.008 | |
| Debt To Assets Ratio | 0.087 | 0.097 | 0.152 | 0.137 | 0.000 | |
| Debt To Equity Ratio | 0.168 | 0.192 | 0.257 | 0.173 | 0.000 | |
| Debt To Capital Ratio | 0.144 | 0.161 | 0.204 | 0.148 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.130 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.925 | 1.968 | 1.695 | 1.262 | 1.054 | |
| Working Capital Turnover Ratio | 0.450 | 0.369 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.355 | 0.268 | -0.940 | -3.616 | -3.568 | |
| Operating Cash Flow Sales Ratio | -0.184 | 0.555 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.206 | 0.905 | 1.435 | 1.140 | 1.164 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -26.831 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -29.858 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.582 | 0.983 | -0.951 | -1.967 | 0.000 | |
| Capital Expenditure Coverage Ratio | -4.851 | 10.531 | -2.300 | -7.162 | -6.100 | |
| Dividend Paid And Capex Coverage Ratio | -4.851 | 10.531 | -2.300 | -7.162 | -6.100 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -29.873 | -5.344 | -1.618 | -3.480 | -8.412 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 93.2% | ▲4.0% | ▲56.7% |
| Ebit Margin | -32.1% | ▲60.6% | ▼-7.1% |
| Ebitda Margin | -25.4% | ▲56.6% | ▼-3.9% |
| Operating Profit Margin | -43.8% | ▲63.4% | ▼-13.6% |
| Pretax Profit Margin | -32.1% | ▲60.6% | ▼-7.1% |
| Continuous Operations Profit Margin | -31.2% | ▲64.9% | ▼-5.8% |
| Net Profit Margin | -31.2% | ▲64.9% | ▼-5.8% |
| Bottom Line Profit Margin | -31.2% | ▲64.9% | ▼-5.8% |
| Current Ratio | 6.123 | ▲3.718 | ▼-2.946 |
| Quick Ratio | 6.123 | ▲3.718 | ▼-2.946 |
| Solvency Ratio | -0.140 | ▲0.159 | ▲1.214 |
| Cash Ratio | 2.023 | ▲0.594 | ▼-3.807 |
| Price To Earnings Ratio | -26.576 | ▼-19.495 | ▼-16.185 |
| Price To Earnings Growth Ratio | 0.668 | ▲0.555 | ▲0.584 |
| Forward Price To Earnings Growth Ratio | 0.668 | ▲0.555 | ▲0.584 |
| Price To Earnings Diluted Ratio | -26.576 | ▼-19.495 | ▼-16.185 |
| Price To Earnings Diluted Growth Ratio | 0.668 | ▲0.555 | ▲0.584 |
| Price To Book Ratio | 4.410 | ▲2.109 | ▲1.932 |
| Price To Sales Ratio | 8.310 | ▲1.527 | ▲5.292 |
| Price To Free Cash Flow Ratio | -37.375 | ▼-50.870 | ▼-28.242 |
| Price To Operating Cash Flow Ratio | -45.080 | ▼-57.294 | ▼-33.202 |
| Debt To Assets Ratio | 0.087 | ▼-0.010 | ▼-0.007 |
| Debt To Equity Ratio | 0.168 | ▼-0.023 | ▲0.010 |
| Debt To Capital Ratio | 0.144 | ▼-0.017 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.130 | ▲0.130 | ▲0.104 |
| Financial Leverage Ratio | 1.925 | ▼-0.043 | ▲0.344 |
| Working Capital Turnover Ratio | 0.450 | ▲0.081 | ▲0.286 |
| Operating Cash Flow Ratio | -0.355 | ▼-0.623 | ▲1.287 |
| Operating Cash Flow Sales Ratio | -0.184 | ▼-0.740 | ▼-0.259 |
| Free Cash Flow Operating Cash Flow Ratio | 1.206 | ▲0.301 | ▲0.036 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲5.366 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲5.971 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.582 | ▼-1.565 | ▼-0.078 |
| Capital Expenditure Coverage Ratio | -4.851 | ▼-15.381 | ▼-2.874 |
| Dividend Paid And Capex Coverage Ratio | -4.851 | ▼-15.381 | ▼-2.874 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -29.873 | ▼-24.529 | ▼-20.128 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.03B | $512.9M | $290.4M | $359.4M | $950.3M | |
| Enterprise value | $937.0M | $331.4M | $208.3M | $351.5M | $604.2M | |
| EV / Sales | 7.58x | 4.38x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -41.10x | 7.89x | -4.76x | -3.80x | -10.18x | |
| EV / Free cash flow | -34.08x | 8.72x | -3.31x | -3.34x | -8.74x | |
| EV / EBITDA | -29.87x | -5.34x | -1.62x | -3.48x | -8.41x | |
| Net debt / EBITDA | 2.89x | 2.93x | 0.64x | 0.08x | 4.82x | |
| Current ratio | 6.12x | 2.40x | 5.07x | 10.79x | 20.96x | |
| Income quality | 0.59x | -0.58x | 0.32x | 0.85x | 0.80x | |
| Graham net-net | $3 | $2 | $2 | $4 | $7 | |
| Tax burden | 97.2% | 103.7% | 100.3% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 103.6% | 100.0% | |
| Working capital | $329.0M | $220.5M | $189.6M | $250.3M | $332.0M | |
| Invested capital | $379.3M | $276.8M | $252.2M | $312.2M | $344.4M | |
| Return on assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% | |
| Operating ROA | -12.2% | -21.8% | -44.4% | -31.7% | -35.1% | |
| Return on tangible assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% | |
| Return on equity | -16.6% | -32.6% | -75.5% | -40.0% | -21.3% | |
| Return on invested capital | -13.6% | -28.4% | -55.1% | -35.1% | -20.8% | |
| Return on capital employed | -14.1% | -28.8% | -55.7% | -35.5% | -20.8% | |
| Earnings yield | -3.8% | -14.2% | -46.6% | -30.2% | -7.8% | |
| Free cash flow yield | -2.7% | 7.4% | -21.6% | -29.3% | -7.3% | |
| Capex / Op. cash flow | -20.6% | 9.5% | -43.5% | -14.0% | -16.4% | |
| Capex / Depreciation | 56.2% | 49.1% | 306.0% | 344.8% | 456.5% | |
| Capex / Sales | 3.8% | 5.3% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 29.4% | 46.5% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 114.4% | 160.8% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 15.3% | 24.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 14d | 1d | 0d | 0d | 0d | |
| Days payables outstanding | 155d | 774d | 654d | 0d | 0d | |
| Operating cycle | 14d | 1d | 0d | 0d | 0d | |
| Cash conversion cycle | -141d | -773d | -654d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+100.4%EV / Sales ▲+72.9%EV / EBITDA ▼-459.0%EV / Op. cash flow ▼-48.993Earnings yield ▲+0.104
Profitability
Return on equity ▲+0.160Return on assets ▲+0.080Return on invested capital ▲+0.149Return on capital employed ▲+0.147Operating ROA ▲+0.096Income quality ▲+1.168Tax burden ▼-0.064
Efficiency
Days sales outstanding ▲+12.741Days payables outstanding ▼-618.663Operating cycle ▲+12.741Cash conversion cycle ▲+631.405Capex / Sales ▼-0.015R&D / Sales ▼-0.463
Balance-sheet strength
Current ratio ▲+3.718Net debt / EBITDA ▼-0.036Working capital ▲+108479000.000Invested capital ▲+102537000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+8.2%EV / Sales n/aEV / EBITDA ▼-255.1%EV / Op. cash flow ▼-30.924Earnings yield ▲+0.040
Profitability
Return on equity ▲+0.047Return on assets ▲+0.116Return on invested capital ▲+0.073Return on capital employed ▲+0.067Operating ROA ▲+0.228Income quality ▼-0.212Tax burden ▼-0.028
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-14.833Net debt / EBITDA ▼-1.927Working capital ▼-3055000.000Invested capital ▲+34992000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-10-16 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.67 According to Analysts Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy
- 2026-10-11 ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Volatility and Risk Monte Rosa Therapeutics has a
- 2026-10-06 Monte Rosa''s MRT-8102 Shows Biomarker Gains in GFORCE-1 Study Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.
- 2026-10-02 Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $11.26 as reported by Nasdaq on October 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee''s continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 19,150 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee''s continued service with the Company through each applicable vesting date, or collectively, the Awards.
- 2026-10-01 Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
- 2026-10-01 Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while outlining plans to advance the treatment into multiple Phase 2 studies.
- 2026-10-01 Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to atherosclerotic plaque progression and instability, and IL-1 β , all established key pathogenic drivers of ASCVD, were reduced to levels comparable to normal physiological levels seen in the healthy volunteer population of Phase 1 study MRT-8102 was safe and well tolerated over four weeks of dosing and four weeks of follow-up, with no serious adverse events, treatment-emergent adverse event rates comparable to placebo, and no evidence of increased infection risk Phase 2 trials planned across coronary artery disease (GFORCE-2), gout (GEMINI-1), and moderate to severe hidradenitis suppurativa (GALAXY-1) Company to host conference call and webcast today, Oct. 1, at 8:00 a.m. ET BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NEK7/NLRP3 pathway.
- 2026-09-30 Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m.
- 2026-09-28 Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE Bank of America Corp DE purchased a new position in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 254,561 shares of the company''s stock, valued at approximately $6,160,000. Bank of
- 2026-09-21 Analysts Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Target Price at $28.50 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a